WO2004076475A1 - A method of generating metal chelating affinity ligands - Google Patents
A method of generating metal chelating affinity ligands Download PDFInfo
- Publication number
- WO2004076475A1 WO2004076475A1 PCT/SE2003/001903 SE0301903W WO2004076475A1 WO 2004076475 A1 WO2004076475 A1 WO 2004076475A1 SE 0301903 W SE0301903 W SE 0301903W WO 2004076475 A1 WO2004076475 A1 WO 2004076475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metal chelating
- scaffold
- ligand
- base matrix
- separation medium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J45/00—Ion-exchange in which a complex or a chelate is formed; Use of material as complex or chelate forming ion-exchangers; Treatment of material for improving the complex or chelate forming ion-exchange properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3265—Non-macromolecular compounds with an organic functional group containing a metal, e.g. a metal affinity ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
Definitions
- the present invention relates to a method of generating polydentate metal chelating af- finity ligands.
- the invention also encompasses a method of generating a separation medium comprising such ligands, as well as such ligands and such a medium.
- MCAC metal chelate affinity chiOmatography
- IMAC immobilised metal ion adsorption chiOmatography
- IEX ion exchange chromatography
- HIC hydrophobic interaction chromatography
- IMAC utilises matrices that comprises a group capable of forming a chelate with a transition metal ion, which chelate in turn is used as the ligand in chro- matography to adsorb a compound from a liquid.
- the binding strength in IMAC is affected predominately by the species of metal ion, the pH of the buffers and the nature of the ligand used. Since the metal ions are strongly bound to the matrix, the adsorbed protein can be eluted either by lowering the pH or by competitive elution.
- IMAC is useful for separation of proteins or other molecules that present an affinity for the transition metal ion of the matrix. For example, proteins will bind to the matrix upon the presence of accessible histidine, cysteine and tryptophan residues, which all exhibit affinity for the chelated metal.
- proteins are now easily tailored or tagged with one or more histidine residues in order to increase their affinity to metal chelated ligands, and accordingly, metal chelate chromatography has more recently assumed a more important role in the purification of proteins.
- IDA irninodiacetic acid
- IDA coupled to agarose supports and subsequent charged with various metals, such as Cu 2+ , Zn 2+ and Ni 2+ , has been used for capture of proteins and peptides and is also available as commercial resins.
- USP 4,551,271 (Hochuli, assigned to Hoffmann-La Roche Inc.) discloses a metal chelate resin which comprises IDA ligands, in the purification of interferon.
- the resin can be defined by the following formula:
- Me is Ni or Cu.
- the resin can according to the specification be prepared in a known manner by treating agarose with epichlorohydrin or epibromohydrin, reacting the resulting epoxide with iminoacetic acid disodium salt and converting the product into the copper or zinc salt by washing with a copper (II) or zinc solution.
- EP 87109892.7 F. Hoffmann-La Roche AG
- USP 4,877,830 D ⁇ beli et al, assigned to Hoffmann-La Roche Inc.
- NT A nitrilotriacetic acid
- the disclosed matrix is prepared by reacting an amino acid compound of the formula R - HN - (CH 2 ) X - CH(NH 2 ) - COOH, wherein R is an amino protecting group and x is 2, 3 or 4, with bromoacetic acid in alkaline medium and subsequently, after an intermediate purification step, cleaving off the protecting group and reacting this group with an activated matrix.
- R is an amino protecting group and x is 2, 3 or 4
- bromoacetic acid in alkaline medium
- the method of preparation involves separate steps for alkylatmg and deprotecting the amino acid, which steps renders the method time- consuming and hence costly.
- the alkylation chemistry is less efficient, and after deprotection, the product is not well defined regarding rest products from neutralisation and cleavage.
- the material is coupled to a solid support that carries carboxyl functionalities by forming an amide bond.
- this procedure may involve disadvantages, since the media obtained presents the immobilised desired chelat- ing ligand as well as some unreacted carboxylic groups, thus yielding a heterogeneous media.
- mono-N-protected amino acid compounds are expensive starting materials, rendering the overall method even more costly.
- WO 01/81365 (Sigma-Aldrich Co.) discloses a metal chelating composition that according to the specification is capable of forming relatively stable chelates with metal ions and exhibits an improved selectivity for polyhistidine tagged proteins.
- the linkage between the chelator and the resin is an important parameter for the selectivity, and the linkage is a neutral ether, a thioether, a selenoether or an amide.
- the disclosed compositions are coupled to an insoluble carrier, such as Sepha- roseTM according to given examples.
- the chromatographic media is produced in two different ways; either by a solid phase reaction directly on to the pre-activated solid support eventually used in the chromatographic media, or by a separate in solution synthesis of the intermediate product N,N,N',N'-tetrakis (carboxymethyl)-L-cystine that is eventually coupled to the solid support.
- the solid phase synthesis is carried out by adding L-cysteine to a previously epichlorhy- drine activated SepharoseTM gel under alkaline conditions for a prolonged reaction time (18h), followed by washings.
- bromoacetic acid is added, again under alkaline conditions and a prolonged reaction time (72 h), and again followed by washings, and eventually capping of remaining free amino groups present on the gel with acetic acid anhydride.
- Solid phase synthesis in this way offers poor control of the reaction and potential side reactions, and thereby yields a less homogeneous product.
- N,N,N',N'-tetrakis (carboxymethyl)-L-cystine has to be reduced to N,N -bis (carboxymethyl)-L-cysteine using tris (carboxyethyl) phos- phine under alkaline conditions.
- This material can finally be used for coupling to a pre- activated solid support forming the chromatographic media.
- This synthetic method is elaborate and depends on a large excess of reagents to form the desired product that is eventually purified under specific chromatographic conditions, followed by reduction as an additional synthetic step, and is thereby less suited for use in large-scale production.
- one object of the present invention is an improved method of generating polydentate metal chelating affinity ligands for subsequent coupling to a base matrix, which method utilises cost-effective and easily available starting materials and reagents and provides high yields.
- This can be achieved as defined in claim 1.
- Another object of the present invention is to enable a careful selection of the ligands that are immobilised onto a base matrix for use in IMAC. This can be achieved by a method of generating a separation medium comprising polydentate metal chelating affinity ligands coupled to a base matrix, wherein the coupling chemistry is well defined and easy to control.
- a further object of the invention is to provide such a method, which results in a homoge- nous product.
- Yet a further object of the invention is to provide a method as discussed above, which also allows introducing two or more functionalities, which functionalities may be of the same kind or different.
- Another object of the present invention is to provide ligands for immobilised metal affinity chromatography, which ligands presents an improved handle for coupling to a base matrix and hence an improved coupling efficiency as compared to prior art ligands.
- An additional object of the present invention is to provide a chromatographic medium, which in use for immobilised metal affinity chromatography (IMAC) yields a low leak- age of metal ions .
- IMAC immobilised metal affinity chromatography
- Another object of the invention is to provide a method of generating a diverse library of metal chelating affinity ligands based on the same scaffold, which method can be used for ligand optimisation towards a specific application.
- Figure 1 provides a schematic illustration of the general route to produce a separation medium that comprises polydentate metal chelating affinity chromatography ligands according to the invention.
- Figure 2 (a) and (b) illustrate purification of Maltose Binding Protein with (His) 6 -tail (MBP-His) using IMAC separation medium prepared according to the invention. More specifically, Figure 2(a) is the chromatogram, while Figure 2(b) is an enlargement of the gradient part of said chromatogram.
- the curve at A280 nm is denoted A
- the percentage (%) of elution buffer is denoted B
- the conductivity is denoted C.
- Figure 3 shows SDS-PAGE analyses of fractions from IMAC purification of MBP-His. Fraction numbering as in Figure 2 chromatogram.
- the nickel-binding capacity of this prototype was determined to 16 ⁇ mol Ni/ml and the metal leakage to 4%.
- Figure 5 shows the results of the nickel capacity test performed on a separation medium according to the invention as described in Example 5.
- separation medium is used herein for a material useful e.g. as packing of a chromatography column, and more specifically consists of one or more ligands coupled to a base matrix.
- the base matrix acts as a carrier, while the ligands provide functionalities that interact with target substances in chromatography.
- spacer is used for a chemical entity that distances a ligand from the base matrix.
- ligand means herein a chemical entity capable of binding target substances. Such target substances may be either a compound, which it is desired to isolate or remove by chromatography, or alternatively an analytical target substance.
- polydentate metal chelating ligands refers to ligands with two or more donor atoms that can coordinate to, i.e. chelate, a metal simultaneously.
- a polydentate ligand has two or more donor atoms and occupies two or more sites in a coordination sphere.
- metal chelating functionalities refers to the groups that provides donor atoms. Usually, the functionalities are distanced from each other and hence the term “ligand arm” is used for each functionality.
- gel is used for a separation matrix, which is in the form of a gel. Detailed description of the invention
- the present invention relates to a method of generating at least one polydentate metal chelating affinity ligand, which method comprises the steps of
- Xi, X 2 and X 3 irrespective of each other are sp - or sp -hybridised carbon atoms or heteroatoms, X 4 is a nucleophile and m is an integer of 0-2;
- step (b) providing at least one polydentate metal chelating affinity ligand arm, optionally in a form wherein the metal chelating functionalities are protected, on each scaffold by derivatisation of the nucleophilic X 4 groups of said scaffolds while retaining the cyclic structure of the scaffold; (c) ring-opening at the bond between the carbonyl and the sulphur of the derivatised scaffold by adding a reagent that adds one or more metal chelating affinity ligand arms to the scaffold; and, if required, (d) deprotecting the functionalities of the ligand arm(s) provided in step (b).
- the scaffold of step (a) can be provided as a solid or, preferably, in a solvent.
- Xi, X 2 and X 3 are carbon atoms.
- one or more of X l5 X 2 and X 3 are heteroatoms, i.e. selected from the group comprised of oxygen, sulphur, nitrogen and/or silica, provided that said heteroa- tom does not interfere in the subsequent use of the ligands.
- X 4 is any suitable nucleophilic group that enables derivatisation.
- X 4 is -NH 2 .
- m can be any integer of 0-2, i.e. 0, 1, or 2. As appears from the method steps, the value of m will decide the number of atoms between the ligand arms and its attachment point to a base matrix when it is developed into a separation medium.
- m is 1 and the scaffold is homocysteine thiolactone.
- homocysteine thiolactone can be used in pure or racemate form.
- Homocysteine thiolactone is commercially available, e.g. from Aldrich, catalogue no. HI, 580-2, and CAS no. 6038-19-3.
- step (b) the derivatisation is performed by adding a suitable derivatisation agent comprised of a first part, which is electrophilic and hence capable of reacting with X 4 of Formula (I), and a second part, which comprises a metal chelating functionality.
- a suitable derivatisation agent comprised of a first part, which is electrophilic and hence capable of reacting with X 4 of Formula (I), and a second part, which comprises a metal chelating functionality.
- the first part of the derivatisation agent i.e. electrophilic part
- C C
- C-Y wherein Y represents for example a halogen, such as Br, I, Cl, or a mesylate, or a tosylate group
- W is for example formed from N-hydrosuccinimide, pentafluorophenol, para-nitrophenol or isopropyl chloroformate.
- the derivatisation is provided by adding two derivatisation agents, each one of which comprises different or identical metal chelating functionalities, herein denoted Li and L 2 .
- the electrophilic parts of the agents are preferably of the same nature in order to facilitate the derivatisation.
- more than two different or identical metal chelating functionali- ties are introduced by derivatisation of X 4 , preferably by use of two or more different steps, as is realised by the skilled person in this field. Accordingly, multiple functionalities are easily provided in the same, polydentate metal chelating affinity ligand.
- the derivatisation agent(s) used in the present method can either comprise the metal chelating functionality in protected form, wherein the donor atoms are unavailable for reaction during the derivatisation of the scaffold, or in non-protected form.
- said protecting group should be easy to remove in a subsequent step.
- the protecting group is either acid labile, such as an alkyl group, or base labile, such as a tert-butyl group.
- the protecting group is a CH 2 CH 3 group.
- Various metal chelating functionalities are known in this field, and can in principle be any electron-donating group.
- the metal chelating functionalities used in the present method are selected from the group that consists of aromates, heterocyclic derivatives, such as pyridine, thiophene, furan and imidazole, acids, esters, ketones, amides, sulphones, sulphonamides, nitrile, carbon- carbon double and triple bonds.
- the derivatisation agent is a halogenated carboxylic acid ester, such as a halogenated carboxylic acid alkyl ester.
- a halogenated carboxylic acid alkyl ester is NH 2 .
- Methods for reacting an NH 2 group with a group carrying a halogen or another leaving group are well known in this field and are conven- iently performed at ambient temperature in a solvent such as N,N-dimethylformamide (DMF).
- DMF N,N-dimethylformamide
- the derivatisation agent in order to provide two metal chelating affinity ligand arms on each scaffold by the derivatisation, is used in a molar ratio of 2:1 to the scaffold.
- the skilled person can easily monitor the reaction and confirm the derivatisation obtained by a conventional method such as LC-MS.
- the present in- vention provides a less complex synthetic route to polydentate metal chelating affinity ligands than WO 01/81365. Due to the advantageous chemistry, the present method also results in a more homogenous product.
- the yields obtained according to the present method can be as high as 90%, and the starting materials are at present readily available to a reasonable cost.
- step (c) ring-opening is provided at the bond between the carbonyl and the sulphur of the derivatised scaffold by adding a reagent, which adds one or more metal chelating affinity ligand arms of the scaffold.
- a reagent which adds one or more metal chelating affinity ligand arms of the scaffold.
- the ring opening will also result in a handle available for subsequent coupling to a base matrix in the form of the thiophilic group, which due to its nucleophilic nature provides convenient coupling chemistry.
- the ring opening is hydrolysis by addition of alkali hydroxide, such as NaOH, in which case the carbonyl of the scaffold is transformed into a carboxylic group.
- the ring opening is performed with a different reagent, one or more different metal chelating functionalities can be introduced.
- the ring opening is aminolysis, in which case the nitrogen carries one or more metal chelating functionalities.
- the reagent is defined by the general formula II:
- L 3 and L 4 comprise metal chelating functionalities, which can be the same or different. Further, in one embodiment, said ligand arms L 3 and L are the same as those provided in step (b) by the derivatisation.
- a step of deprotection is preferably performed.
- said deprotection is performed as a separate step that follows step (c), and can be achieved by adding a base or an acid, as indicated above.
- the chemistry useful for protection/deprotection of functionalities are well-known in this field, and the skilled person in this field can easily perform such steps.
- the deprotection is performed in the same step as the ring-opening, i.e. essentially simultaneously.
- the great advantage of this embodiment is that polydentate metal chelating affinity ligands can be generated using a simple procedure that only comprises two steps. Conse- quently, this embodiment provides a less complex method than the prior art methods for the synthesis of polydentate metal chelating affinity ligands.
- the derivatisation agent comprises a base labile group
- this step is provided by addition of sodium hydroxide. The hydrolysis is advantageously performed at ambient temperature for e.g. 1-2 hours.
- step (c) this step is provided by addition of an acid, such as HCl.
- steps (a) and (b) have been performed earlier to provide a ready-derivatised scaffold
- steps (a) and (b) have been performed earlier to provide a ready-derivatised scaffold
- the present invention also encompasses a method, wherein the carboxymethylation of the scaffold has been per- formed earlier.
- the product so obtained is coupled via its sulphur to a base matrix in order to produce a separation medium.
- a separation medium is useful for isolation of target substances, for analytical purposes etc.
- the base matrix used in the present method can be of any material suitable for the intended use.
- the base matrix is commonly in beaded or monolithic form and made from natural polymers, e.g. agarose or dextran, or synthetic polymers, such as divinylbenzene or styrene.
- the base matrix can e.g. be in the form of a gel.
- suitable porous polymer beads thereof are either easily per- formed by the skilled person in this field according to standard methods, such as inverse suspension gelation (S Hjerten: Biochim Biophys Acta 79(2), 393-398 (1964) or spin- ning disk technique (see e.g.
- natural polymer beads are obtained from commercial sources, such as Amersham Biosciences AB, Uppsala, Sweden.
- Illustrative tradenames of such useful natural polymer beads are e.g. of the kind known as SepharoseTM or SephadexTM.
- the base matrix is comprised of cross-linked synthetic polymers, such as styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides etc.
- synthetic polymers such as styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides etc.
- Such polymers are easily produced according to standard methods, see e.g. "Styrene based polymer supports devel- oped by suspension polymerization” (R Arshady: Chimica e L'Industria 70(9), 70-75 (1988)).
- a commercially available product such as SourceTM (Amersham Biosciences AB, Uppsala, Sweden) can be surface-modified according to the invention.
- the base matrix can e.g. be a membrane, a filter, one or more chips, surfaces, capillaries etc.
- the reactive groups of the base matrix are allyl groups i.e. carbon- carbon double bonds.
- a commercially available base matrix, which already exhibits allyl groups is used.
- the allyl groups are provided according to well known methods.
- the present base matrix has been allylated by treatment with an epoxide carrying an allyl functionality at suitable temperatures and reaction times.
- an epoxide carrying an allyl functionality is allyl glycidyl ether (AGE).
- the sulphur group of the ligand is coupled to the base matrix via the activated allyl group of allyl glycidyl ether (AGE).
- the sulphur group will be attached to the base matrix by a spacer comprising ether groups and hydroxy groups, and the separation medium can be defined as base matrix -O-CH 2 -CHOH-CH 2 -O-CH 2 -CHOH-CH 2 -S- ligand.
- thiol-containing ligands are used, such as opening of epoxide or radical addition to double bonds.
- said allyl groups are activated by bromination or alternatively, the coupling is a free radical reaction.
- the free radical used can be any suitable commercially available initiator, UV etc.
- a second aspect of the present invention is a polydentate metal chelating affinity ligand or a separation medium comprising at least one, preferably a plurality of, polydentate metal chelating affinity ligands coupled to a base matrix, which medium has been generated by a method as described above.
- the metal chelating af- finity ligands are tridentate.
- Such a separation medium can then be charged with a suitable metal ion, such as Cu(II), Zn(II), Ni(II), Ca(II), Co(II), Mg(II), Fe(III), Al(III), Ga(III), Sc(III) etc, and used according to well known principles of IMAC, e.g. as outlined in the section "Background" above.
- Ni 2+ is used.
- the present polydentate metal chelating affinity ligands are tridentate ligands are defined by the formula -S - (CH 2 )n - CH(COOH) - N(CH 2 CQO _ ) 2 .
- the present separation medium which comprises polydentate metal chelating affinity ligands coupled to a base matrix, is defined by the general formula
- a third aspect of the invention is the use of homocysteine thiolactone as a starting material in the preparation of polydentate metal chelating ligands, preferably be the method described above.
- the invention also encompasses the use of a carboxymethylated scaffold such as homocysteine thiolactone in the preparation of polydentate metal chelating ligands. In the most advantageous embodiment, said use is as defined above.
- homocysteine thiolactone is commercially available.
- kits which comprises a scaffold as defined by the general formula (I) above, which kit comprises said scaffold in a solid state to- gether with instructions, preferably written, for use thereof in the manufacture of metal chelating affinity ligands or a separation medium comprising polydentate metal chelating affinity ligands coupled to a base matrix.
- a kit according to the invention comprises any other form of the scaffold, such as a partly or fully deriva- tised scaffold, together with liquids and/or reagents suitable for performing the method according to the invention.
- a kit is comprised of a scaffold reacted according to the present method except the deprotection, in which case the kit also comprises a suitable reagent for deprotection, such as a base or an acid, together with instructions for use.
- the present invention also encompasses a chromatography column packed with a medium according to the invention.
- the column can be of any size, such as for large-scale production or lab-scale, or suitable for analytical purpose.
- the column can also be combined with separation medium and optionally liquids into a second kind of kit, which is also encompassed by the present invention.
- the kit according to the invention comprises metal ions, such as Ni 2+ ions.
- the present invention also relates to a process of separating a target substance from a liquid, which process comprises to provide a separation medium as defined above, to charge said medium with suitable metal ions to form chelates and to contact said medium with the liquid to adsorb the target substance thereon.
- the process also comprises a step of eluting the target substance from the separation medium by adding a liquid that desorbs the target compound from the separation medium.
- the elution is obtained by using a liquid that comprises a decreasing pH gradient or by applying a gradient giving an increasing imidazole concentration.
- the general principles of chromatography for separating a target substance as discussed above are well-known in this field (see e.g. Protein Purification - Principles, High resolution methods and Applications (J-C Jansson and L. Rydenl989 VCH Publishers)), and the skilled person in this field can easily adopt the necessary parameters for use of the present process.
- the present invention relates to a procedure of generating one or more diverse libraries of metal chelating affinity ligands for screening and optimising purposes.
- one arm carrying a dentate can be kept constant while other arms are selected in terms of optimal performance.
- one or more of the above-discussed L ls L 2 , L 3 and L can be varied in order to identify the optimal form, and subsequently, once the optimised form has been identified, it is kept constant while other(s) are varied.
- the procedure of optimisation provides a tool to manufacture a separation medium comprising optimal, selected ligands.
- Figure 1 provides a schematic illustration of the general route to produce a separation medium that comprises polydentate metal chelating affinity chromatography ligands according to the invention.
- the first step corresponds to step (b) of the present method, i.e. a derivatisation
- the second step is a hydrolysis to open up the ring of the derivatised scaffold and the last step is immobilisation i.e. coupling of the ligand so produced to a base matrix.
- the second step is advantageously a combined ring-opening and deprotection.
- R denotes either hydrogen or alternatively an acid or base labile protecting group.
- Figure 2 (a) and (b) illustrate purification of Maltose Binding Protein with (His) 6 -tail (MBP-His) using IMAC separation medium according to the invention. More specifically, Figure 2(a) is the chromatogram, while Figure 2(b) is an enlargement of the gradi- ent part of said chromatogram.
- the curve at A280 nm is denoted A
- the percentage (%) of elution buffer is denoted B
- the conductivity is denoted C.
- Figure 3 shows SDS-PAGE analyses of fractions from IMAC purification of MBP-His. Fraction numbering as in Figure 2 chromatogram.
- the nickel-binding capacity of this prototype was determined to 16 ⁇ mol Ni/ml and the metal leakage to 4%, as explained in example 5 below.
- Figure 5 shows the results of the nickel- capacity test performed on a separation medium according to the invention as described in Example 5. More specifically, the X axis shows the ligand density while the Y axis shows the nickel-binding. It appears clearly that the nickel-binding capacity increases linearly with the ligand density and that the slope is close to one.
- Example 1 Carboxymethylation of scaffold to provide NJSf-bis(ethyl-carboxymethyl ester +/-homocysteine thiolactone
- the D/L homocysteine thiolactone (4.5g, 29.22 mmol) was dissolved in lOOmL DMF.
- bromo- acetic acid ethyl ester (9.76 g, 58.44 mmol, 6.48 mL)
- KI 4.850 g, 29.22mmol
- NaHCO 3 (14.727g, 175 mmol
- the solvent was evaporated, the resulting solid redissolved in CHC1 3 , extracted with H 2 O X 2.
- the organic phase was finally dried over Na 2 SO 4 , filtered and evaporated.
- the product was purified on flash column chromatography (toluene: ethyl acetate 3:1). Yield:7.636g (26.422mmol), 90%.
- Example 2 Hydrolysis to provide N,N-bis(carboxymethyl)+/-homocysteine and stability test
- N,N-bis(ethyl carboxymethyl ester)+/-homocysteine thiolactone (50 mg, 0.173 mmol) prepared as described in example 1 above, was dissolved in ImL 1M NaOH. In a lOOmL round-bottomed flask. The reaction mixture was stirred at ambient temperature for 100 minutes. The reaction was followed to completion until no starting material was visible according to LC-MS.
- the crude product was freeze-dried.
- Example 3 Coupling of the product obtained from example 2 to allylated agarose using AGE
- Example 4 Purification of Maltose Binding Protein with (HisV-tail (MBP-His) using an IMAC separation medium generated according to the invention and metal leakage test
- 140+140+720 mM 1 M), pH adjusted to 7.4 with NaOH and final volume to 1000 ml. (Buffer also contains 6 mM KC1).
- Elution Buffer (IMAC B -buffer): Prepared in the same way as IMAC A-buffer, but also imidazole was added to 500 mM (from 2.0 M stock of imidazole-HCl, pH 7.4) before final adjustment of pH and volume.
- Ni 2+ -sulphate solution 100 mM in water. Filter 0.2 um. pH « 4.6. Sample buffer and running conditions according to Instructions for ExcelGelTM (Amer- sham Biosciences, Uppsala, Sweden).
- Sample prep Samples were mixed 1+1 with 2 x sample buffer (for purifications with large amounts of target protein) or 1 volume sample + 1/3 volume 4x sample buffer (purifications with small amounts of target protein).
- (4x sample buffer 100 mM Tris-HAc pH 7.5, 2 % SDS.) Heating at 95°C for 3-5 minutes.
- Electrophoresis In a MultiphorTM II (Amersham Biosciences, Uppsala, Sweden) apparatus at 15° C (circulating cooling bath).
- the nickel (Ni ) binding capacity of a separation medium according to the invention was determined chromatographically using an AKTATM Explorer 10 system (Amersham Biosciences, Uppsala, Sweden) equipped with a UV/Vis DAD detector. The test was performed on gel to which N,N-bis(carboxymethyl)+/-homocysteine had been coupled according to earlier description, and packed in 1-ml HR5/5 columns ( Figure 4). This re- suit was compared with the ligand density present on the gel as determined by elemental analysis (nitrogen analysis, each ligand containing one nitrogen atom). The correlation between nickel-binding capacity and ligand density was considered to be very good, i.e. one ligand is carrying one metal ion. Typical results are shown in Figure 5.
- NiSO solution was injected to load the gel with Ni 2+ ions. Excess metal was removed by washing with water and phosphate buffer (20 mM PO 4 , 500 mM NaCl, pH 7.4). The nickel ions bound to the gel were eluted with EDTA, which is a very strong chelator and efficiently strips the metal ions from the gel. The peak area of the green coloured Ni- EDTA complex eluted was measured at 372 nm. A linear calibration curve was established from solutions with different concentrations of Ni-EDTA and was used for quantification. The nickel-binding capacity (Figure 4, peak 1) was given as ⁇ mol Ni/ml packed gel.
- the metal leakage was considered to be very low for all tested gels prepared according to the present invention; typically the leakage was 4 %.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Polyesters Or Polycarbonates (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200380110021A CN100595206C (en) | 2003-02-28 | 2003-12-08 | Method of generating metal chelating affinity ligands |
AU2003303976A AU2003303976B2 (en) | 2003-02-28 | 2003-12-08 | A method of generating metal chelating affinity ligands |
CA2517231A CA2517231C (en) | 2003-02-28 | 2003-12-08 | A method of generating metal chelating affinity ligands |
KR1020057015945A KR101060896B1 (en) | 2003-02-28 | 2003-12-08 | Methods of Forming Metal Chelate Affinity Ligands |
DE60331370T DE60331370D1 (en) | 2003-02-28 | 2003-12-08 | METHOD FOR GENERATING METAL CHELEFFINITY LIGANDS |
AT03816091T ATE457993T1 (en) | 2003-02-28 | 2003-12-08 | METHOD FOR GENERATING METAL CHELATE AFFINITY LIGANDS |
JP2004568813A JP5015426B2 (en) | 2003-02-28 | 2003-12-08 | Method for synthesizing metal chelate affinity ligand |
EP03816091A EP1597269B1 (en) | 2003-02-28 | 2003-12-08 | A method of generating metal chelating affinity ligands |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300567-5 | 2003-02-28 | ||
SE0300567A SE526214C2 (en) | 2003-02-28 | 2003-02-28 | One way to generate metal chelating affinity ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004076475A1 true WO2004076475A1 (en) | 2004-09-10 |
Family
ID=20290555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2003/001903 WO2004076475A1 (en) | 2003-02-28 | 2003-12-08 | A method of generating metal chelating affinity ligands |
Country Status (13)
Country | Link |
---|---|
US (2) | US7005071B2 (en) |
EP (1) | EP1597269B1 (en) |
JP (1) | JP5015426B2 (en) |
KR (1) | KR101060896B1 (en) |
CN (1) | CN100595206C (en) |
AT (1) | ATE457993T1 (en) |
AU (1) | AU2003303976B2 (en) |
CA (1) | CA2517231C (en) |
DE (1) | DE60331370D1 (en) |
ES (1) | ES2340032T3 (en) |
GB (1) | GB2398782B (en) |
SE (1) | SE526214C2 (en) |
WO (1) | WO2004076475A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006522332A (en) * | 2003-03-05 | 2006-09-28 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Production method of affinity ligand |
JP2006523308A (en) * | 2003-03-05 | 2006-10-12 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Preparation of ligands for hydrophobic interaction chromatography |
WO2007137752A1 (en) * | 2006-05-26 | 2007-12-06 | Ge Healthcare Bio-Sciences Ab | A method for generating metal chelating affinity ligands |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0103084D0 (en) * | 2001-09-14 | 2001-09-14 | Amersham Pharm Biotech Ab | Generation of ion exchange media |
AU2003286553A1 (en) * | 2002-10-18 | 2004-05-04 | Promega Corporation | Methods for separating molecules |
SE526214C2 (en) * | 2003-02-28 | 2005-07-26 | Amersham Biosciences Ab | One way to generate metal chelating affinity ligands |
EP1599286B1 (en) * | 2003-03-05 | 2008-12-24 | GE Healthcare Bio-Sciences AB | A method of preparing multi-modal anion-exchange ligands |
WO2008057108A2 (en) * | 2006-01-27 | 2008-05-15 | Los Alamos National Security, Llc | Chirality-based separation of carbon nanotubes |
US20070256976A1 (en) * | 2006-04-10 | 2007-11-08 | Boyes Barry E | Metal-coated sorbents as a separation medium for HPLC of phosphorus-containing materials |
US7628915B2 (en) * | 2006-12-08 | 2009-12-08 | Varian, Inc. | Metal cyano bonded phases |
CN101396650B (en) * | 2007-09-26 | 2010-12-22 | 中国科学院大连化学物理研究所 | Titanium ion fixation affinity chromatography material and preparation and use thereof |
HU230585B1 (en) | 2012-05-30 | 2017-01-30 | Budapesti Műszaki és Gazdaságtudományi Egyetem | Carriers complexed with lanthanide metal ions capable for peptid absorption and isolation |
SG11201407806YA (en) * | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Mixed multifunctional metal affinity surfaces for reducing aggregate content in protein preparations field |
CN113351190B (en) * | 2020-02-20 | 2023-05-30 | 中国科学院大连化学物理研究所 | Immobilized metal ion affinity chromatography microsphere material and preparation and application thereof |
CN115583710A (en) * | 2022-07-19 | 2023-01-10 | 江苏驰佳环保科技有限公司 | Chelating agent and preparation method thereof |
CN116393174B (en) * | 2023-04-04 | 2024-06-21 | 大连理工大学 | Catalyst for preparing glycolide and polyglycolide simultaneously and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4551271A (en) * | 1983-03-03 | 1985-11-05 | Hoffmann-La Roche Inc. | Purification of interferon by metal chelate chromatography |
US4877830A (en) * | 1986-07-10 | 1989-10-31 | Hoffmann-La Roche Inc. | Metal chelate resins |
WO1994022492A1 (en) * | 1993-03-31 | 1994-10-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Type s3n2 chelators for radioactive isotopes, their metal complexes and their diagnostic and therapeutical use |
WO2001081365A2 (en) * | 2000-04-24 | 2001-11-01 | Sigma-Aldrich Co. | Metal chelating compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434151A (en) * | 1982-11-08 | 1984-02-28 | Medi-Physics, Inc. | Bifunctional chelating agents |
ZA841395B (en) * | 1983-03-03 | 1984-10-31 | Hoffmann La Roche | Purification of interferon |
US4595656A (en) * | 1984-01-06 | 1986-06-17 | Becton Dickinson & Company | Coupling agents and products produced therefrom |
WO1986000897A1 (en) * | 1984-07-19 | 1986-02-13 | University Of Florida | Novel radiopharmaceuticals and chelating agents useful in their preparation |
DE4311023C2 (en) | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunctional chalcogen atom-interrupted chelating agents of type XN¶1¶S¶1¶O¶1¶ for radioactive isotopes, their metal complexes, processes for their preparation and pharmaceutical compositions containing them |
FR2761691B1 (en) * | 1997-04-03 | 1999-05-14 | Oreal | THIOL TERMINAL FUNCTION POLYMERS |
IL135050A0 (en) * | 1997-09-24 | 2001-05-20 | Genentech Inc | Insulin-like polypeptide and uses therefor |
CN1153606C (en) * | 1998-04-30 | 2004-06-16 | 吉利斯德股份有限公司 | Chelate-foming filter, process for producing the same, and method of purifying liquid with the filter |
SE9802214D0 (en) * | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | Ion exchanger and its use |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
JP2000351776A (en) * | 1999-04-08 | 2000-12-19 | Kuraray Co Ltd | Production of optically active homocysteinethiolactone salt and its intermediate |
JP2001199980A (en) * | 2000-01-21 | 2001-07-24 | Kuraray Co Ltd | Method of manufacturing for optically active homocysteine thiolactone salt |
JP2002308882A (en) * | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | Thienopyrimidine derivative |
SE0103084D0 (en) * | 2001-09-14 | 2001-09-14 | Amersham Pharm Biotech Ab | Generation of ion exchange media |
SE526214C2 (en) * | 2003-02-28 | 2005-07-26 | Amersham Biosciences Ab | One way to generate metal chelating affinity ligands |
-
2003
- 2003-02-28 SE SE0300567A patent/SE526214C2/en not_active IP Right Cessation
- 2003-10-30 GB GB0325329A patent/GB2398782B/en not_active Expired - Lifetime
- 2003-10-31 US US10/699,058 patent/US7005071B2/en not_active Expired - Lifetime
- 2003-12-08 ES ES03816091T patent/ES2340032T3/en not_active Expired - Lifetime
- 2003-12-08 JP JP2004568813A patent/JP5015426B2/en not_active Expired - Lifetime
- 2003-12-08 WO PCT/SE2003/001903 patent/WO2004076475A1/en active Application Filing
- 2003-12-08 EP EP03816091A patent/EP1597269B1/en not_active Expired - Lifetime
- 2003-12-08 CA CA2517231A patent/CA2517231C/en not_active Expired - Lifetime
- 2003-12-08 KR KR1020057015945A patent/KR101060896B1/en active IP Right Grant
- 2003-12-08 AU AU2003303976A patent/AU2003303976B2/en not_active Expired
- 2003-12-08 DE DE60331370T patent/DE60331370D1/en not_active Expired - Lifetime
- 2003-12-08 AT AT03816091T patent/ATE457993T1/en not_active IP Right Cessation
- 2003-12-08 CN CN200380110021A patent/CN100595206C/en not_active Expired - Lifetime
-
2005
- 2005-10-06 US US11/244,603 patent/US20060027501A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4551271A (en) * | 1983-03-03 | 1985-11-05 | Hoffmann-La Roche Inc. | Purification of interferon by metal chelate chromatography |
US4877830A (en) * | 1986-07-10 | 1989-10-31 | Hoffmann-La Roche Inc. | Metal chelate resins |
WO1994022492A1 (en) * | 1993-03-31 | 1994-10-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Type s3n2 chelators for radioactive isotopes, their metal complexes and their diagnostic and therapeutical use |
WO2001081365A2 (en) * | 2000-04-24 | 2001-11-01 | Sigma-Aldrich Co. | Metal chelating compositions |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006522332A (en) * | 2003-03-05 | 2006-09-28 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Production method of affinity ligand |
JP2006523308A (en) * | 2003-03-05 | 2006-10-12 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Preparation of ligands for hydrophobic interaction chromatography |
JP4660472B2 (en) * | 2003-03-05 | 2011-03-30 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Production method of affinity ligand |
WO2007137752A1 (en) * | 2006-05-26 | 2007-12-06 | Ge Healthcare Bio-Sciences Ab | A method for generating metal chelating affinity ligands |
US7988858B2 (en) | 2006-05-26 | 2011-08-02 | Ge Healthcare Bio-Sciences Ab | Method for generating metal chelating affinity ligands |
Also Published As
Publication number | Publication date |
---|---|
KR20050105496A (en) | 2005-11-04 |
KR101060896B1 (en) | 2011-08-30 |
ES2340032T3 (en) | 2010-05-28 |
GB2398782B (en) | 2005-10-19 |
US7005071B2 (en) | 2006-02-28 |
DE60331370D1 (en) | 2010-04-01 |
CA2517231A1 (en) | 2004-09-10 |
US20060027501A1 (en) | 2006-02-09 |
EP1597269A1 (en) | 2005-11-23 |
JP2007528835A (en) | 2007-10-18 |
ATE457993T1 (en) | 2010-03-15 |
GB2398782A (en) | 2004-09-01 |
CN1756762A (en) | 2006-04-05 |
GB0325329D0 (en) | 2003-12-03 |
EP1597269B1 (en) | 2010-02-17 |
SE0300567D0 (en) | 2003-02-28 |
AU2003303976A1 (en) | 2004-09-17 |
SE0300567L (en) | 2004-10-28 |
SE526214C2 (en) | 2005-07-26 |
JP5015426B2 (en) | 2012-08-29 |
AU2003303976B2 (en) | 2010-07-15 |
US20040168983A1 (en) | 2004-09-02 |
CA2517231C (en) | 2013-02-05 |
CN100595206C (en) | 2010-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060027501A1 (en) | Method of generating metal chelating affinity ligands | |
US7988858B2 (en) | Method for generating metal chelating affinity ligands | |
JP5015780B2 (en) | Organosilane and substrate bonded thereto | |
EP2164591B1 (en) | Method for preparation of a biomolecule adsorbent | |
US20100016564A1 (en) | Method of preparing an immobilised metal ion chromatography adsorbent and methods of purifying proteins, peptides or polynucleotides | |
US20220258130A1 (en) | Chromatography Media | |
JP4570052B2 (en) | Preparation of ligands for hydrophobic interaction chromatography | |
AU610734B2 (en) | Polyethyleneimine matrixes for affinity chromatography | |
EP0455269B1 (en) | Packing for use in resolution | |
US7175767B2 (en) | Preparation of a metal chelating separation medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003816091 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3442/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003303976 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2517231 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057015945 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004568813 Country of ref document: JP Ref document number: 20038B00219 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057015945 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003816091 Country of ref document: EP |